Press Releases

    • March 1, 2018

    Nemaura Announces Expansion of Manufacturing Capabilities for SugarBEAT® Commercial Launch

    LOUGHBOROUGH, England–(BUSINESS WIRE)–Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system...

    Read more
    February 9, 2018

    Nemaura Medical Inc. Reports Third Quarter 2017 Financial Results

    LOUGHBOROUGH, England–(BUSINESS WIRE)–Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system...

    Read more
    January 31, 2018

    Nemaura Announces Positive Results for its SugarBEAT® European Clinical Program

    LOUGHBOROUGH, England–(BUSINESS WIRE)–Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system...

    Read more
    January 23, 2018

    Nemaura Medical Inc. Announces Uplisting to NASDAQ Capital Market on January 25, 2018

    LOUGHBOROUGH, England–(BUSINESS WIRE)–Nemaura Medical Inc. (“Nemaura”) (OTCQB: NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive continuous glucose...

    Read more
    December 21, 2017

    Nemaura Announces Completion of SugarBEAT® European Clinical Trial Programme and Positive Interim Results

    LOUGHBOROUGH, England–(BUSINESS WIRE)–Nemaura Medical Inc. (“Nemaura”) (OTCQB: NMRD), a medical technology company developing the wireless sugarBEAT® disposable adhesive skin-patch...

    Read more
    December 6, 2017

    Nemaura Announces Successful SugarBEAT® Interim Precision Study Results

    LOUGHBOROUGH, England–(BUSINESS WIRE)–Nemaura Medical Inc. (OTCQB: NMRD), a medical technology company focused on the development and commercialization of sugarBEAT®,...

    Read more
    November 2, 2017

    Nemaura Medical Inc. Reports Second Quarter 2017 Financial Results

    LOUGHBOROUGH, England–(BUSINESS WIRE)–Nemaura Medical Inc. (OTCQB: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible glucose monitoring system for...

    Read more
    September 26, 2017

    WallStreet Research™ Announces Availability of Corporate Profile Coverage on Nemaura Medical, Inc.

    WallStreet Research™ (WSR), a top-ranked independent research firm with a history spanning over three decades, today announced that it...

    Read more
    September 21, 2017

    Nemaura Announces Successful Interim Results for SugarBEAT® European Clinical Trials

    Nemaura Medical Inc. (OTCQB: NMRD), a medical technology company focused on the development and commercialization of sugarBEAT®, a wireless...

    Read more
    August 29, 2017

    Nemaura Develops Medical Grade SugarBEAT® Android App for Diabetes Management

    Nemaura Medical Inc. (OTCQB: NMRD), a medical technology company focused on the development and commercialization of sugarBEAT®, a wireless...

    Read more